Literature DB >> 15168332

Expression of prostate specific membrane antigen (PSMA) in prostatic adenocarcinoma and prostatic intraepithelial neoplasia.

C Marchal1, M Redondo, M Padilla, J Caballero, I Rodrigo, J García, J Quian, D G Boswick.   

Abstract

The prostatic membrane antigen (PSMA) is a protein that is expressed in the prostatic epithelium. We studied the expression of PSMA in a series of 55 patients with different stages of prostate cancer and we compared the PSMA staining in prostate cancer cells, in high-grade prostatic intraepithelial neoplasia (PIN) and in histologically benign prostatic epithelium for the same specimen. For this purpose archival paraffin-embedded specimens were studied by immunohistochemistry with a monoclonal antibody 7E11-C5.3 against PSMA using the streptavidin-biotin method. The mean percentage of PSMA immunoreactivity was 56.67% in prostate cancer (CaP) cells, and 48.6% in PIN cells, which was significantly higher than benign-appearing prostatic epithelium (5.72%) (for each pair, p<0.001). PSMA expression was greater in CaP with a higher Gleason score (p=0.01), but no relationship was found with serum PSA value. We conclude that PSMA overexpression is detected in high-grade PIN and is associated with a higher Gleason score of prostate cancer. It is a potential marker for studying carcinogenesis and progression of prostate cancer.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15168332     DOI: 10.14670/HH-19.715

Source DB:  PubMed          Journal:  Histol Histopathol        ISSN: 0213-3911            Impact factor:   2.303


  38 in total

1.  NKX3.1 and PSMA are sensitive diagnostic markers for prostatic carcinoma in bone metastasis after decalcification of specimens.

Authors:  Hongying Huang; Sergei R Guma; Jonathan Melamed; Ming Zhou; Peng Lee; Fang-Ming Deng
Journal:  Am J Clin Exp Urol       Date:  2018-10-20

2.  Head to head comparison performance of 99mTc-EDDA/HYNIC-iPSMA SPECT/CT and 68Ga-PSMA-11 PET/CT a prospective study in biochemical recurrence prostate cancer patients.

Authors:  Francisco Osvaldo García-Pérez; Jenny Davanzo; Sergio López-Buenrostro; Clara Santos-Cuevas; Guillermina Ferro-Flores; Miguel A Jímenez-Ríos; Anna Scavuzzo; Zael Santana-Ríos; Sevastián Medina-Ornelas
Journal:  Am J Nucl Med Mol Imaging       Date:  2018-10-20

3.  Laboratory-Based Biomarkers and Liver Metastases in Metastatic Castration-Resistant Prostate Cancer.

Authors:  Patrick M Cotogno; Lahiru K Ranasinghe; Elisa M Ledet; Brian E Lewis; Oliver Sartor
Journal:  Oncologist       Date:  2018-04-26

Review 4.  Oligonucleotide-based theranostic nanoparticles in cancer therapy.

Authors:  Reza Shahbazi; Bulent Ozpolat; Kezban Ulubayram
Journal:  Nanomedicine (Lond)       Date:  2016-04-22       Impact factor: 5.307

Review 5.  [Prostate-specific membrane antigen (PSMA)-based diagnostics and treatment of prostate cancer].

Authors:  A Afshar-Oromieh; I Alberts; C Sachpekidis; A Rominger
Journal:  Urologe A       Date:  2019-12       Impact factor: 0.639

6.  ¹⁸F-DCFBC PET/CT for PSMA-Based Detection and Characterization of Primary Prostate Cancer.

Authors:  Steven P Rowe; Kenneth L Gage; Sheila F Faraj; Katarzyna J Macura; Toby C Cornish; Nilda Gonzalez-Roibon; Gunes Guner; Enrico Munari; Alan W Partin; Christian P Pavlovich; Misop Han; H Ballentine Carter; Trinity J Bivalacqua; Amanda Blackford; Daniel Holt; Robert F Dannals; George J Netto; Martin A Lodge; Ronnie C Mease; Martin G Pomper; Steve Y Cho
Journal:  J Nucl Med       Date:  2015-06-11       Impact factor: 10.057

Review 7.  Multifunctional nanoparticles: cost versus benefit of adding targeting and imaging capabilities.

Authors:  Zhiliang Cheng; Ajlan Al Zaki; James Z Hui; Vladimir R Muzykantov; Andrew Tsourkas
Journal:  Science       Date:  2012-11-16       Impact factor: 47.728

8.  A new perspective for nuclear medicine: expanding the indications for PSMA targeted imaging and therapy.

Authors:  Frederik A Verburg; Markus Luster
Journal:  Eur J Nucl Med Mol Imaging       Date:  2017-07-04       Impact factor: 9.236

9.  68Ga-PSMA-11 PET/CT-derived metabolic parameters for determination of whole-body tumor burden and treatment response in prostate cancer.

Authors:  Christian Schmidkonz; Michael Cordes; Daniela Schmidt; Tobias Bäuerle; Theresa Ida Goetz; Michael Beck; Olaf Prante; Alexander Cavallaro; Michael Uder; Bernd Wullich; Peter Goebell; Torsten Kuwert; Philipp Ritt
Journal:  Eur J Nucl Med Mol Imaging       Date:  2018-05-03       Impact factor: 9.236

10.  Preclinical evaluation of novel glutamate-urea-lysine analogues that target prostate-specific membrane antigen as molecular imaging pharmaceuticals for prostate cancer.

Authors:  Shawn M Hillier; Kevin P Maresca; Frank J Femia; John C Marquis; Catherine A Foss; Nghi Nguyen; Craig N Zimmerman; John A Barrett; William C Eckelman; Martin G Pomper; John L Joyal; John W Babich
Journal:  Cancer Res       Date:  2009-08-25       Impact factor: 12.701

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.